Skip to content
2000
Volume 21, Issue 20
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Abstract: The small-molecular inhibitors targeted JAks (JAK inhibitors) could modulate the cytokines- mediated signaling via the JAK-STAT pathway, which plays an important role in immune regulation and cell proliferation. The JAK inhibitors were previously designed and synthesized to treat diseases involving the hematologic and immune system. Increasing evidence shows that they are quite effective in Atopic Dermatitis (AD), Alopecia Areata (AA), psoriasis, vitiligo, and other autoimmuneinduced dermatologic conditions. Currently, many JAK inhibitors possessing anti-vitiligo activity are being investigated in the laboratory and clinically. In this view, we would like to summarize the applications of these inhibitors with emphasis on the profile of vitiligo, clinical efficacy, dosages, development of new candidates and adverse events through available literature.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557521666210325120233
2021-12-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557521666210325120233
Loading

  • Article Type:
    Review Article
Keyword(s): dermatologic conditions; JAK inhibitors; JAK-STAT; ruxolitinib; tofacitinib; vitiligo
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test